Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Off-Label Marketing Risk Manufacturers of GLP-1 medications may face regulatory scrutiny and legal risks if they promote their products for off-label use or disseminate inaccurate and misleading information
Individual health conditions, lifestyle factors, and unique metabolic profiles must be considered to ensure safety and effectiveness
Phase 3 trials are expected to conclude in May 2026, with potential MHRA and FDA submissions anticipated in 2026 or 2027
Masuda Y, Ohbayashi K, Iwasaki Y
US$ 27.61
US$ 25.20
![Trulicity Lawsuit [2026]](https://www.torhoermanlaw.com/wp-content/uploads/2026/02/Trulicity-Lawsuit-Other-Drugs-and-Manufacturers-Named-in-the-GLP-1-Lawsuits-1.jpg)
US$ 20.39
US$ 20.06
US$ 27.01
US$ 28.66
US$ 20.82
US$ 27.05
US$ 21.54
